Peptide data sheet
Ipamorelin
Performance · NNC 26-0161
Verdict
unprovenThe unproven label reflects a real preclinical and early-pharmacology signal on growth-hormone release paired with an absence of completed human trials establishing the recovery, body-composition, or healthy-aging outcomes people actually search for.
Quick answer
Ipamorelin is a small peptide studied as a selective growth-hormone secretagogue: in research it has been associated with a short-lived rise in growth hormone without much movement in other hormones, which is why it is often described as selective. Most of that data is preclinical or early pharmacology, not completed human outcome trials. It is not FDA-approved and is sold for laboratory research use only.
- Class
- Growth-hormone secretagogue (ghrelin / GH-secretagogue-receptor agonist pentapeptide)
- Half-life
- roughly 2 hours (reported)
- FDA status
- Not FDA-approved. Sold as a research chemical for laboratory research use only; it has not been proven safe or effective for human use.
- WADA banned?
- Yes
Which form actually works?
Injectable (subcutaneous)
Unproven
The form nearly all of the research and user accounts describe. It carries whatever research context ipamorelin has, but that context is mostly preclinical and early pharmacology rather than completed human outcome trials, so the label stays unproven.
Oral / capsule
Risky
Peptides like this are broken down in the gut, so an oral version is widely doubted on absorption grounds and is a common marker of a low-quality or mislabeled product. Treat oral ipamorelin claims with extra skepticism.